Payment overview · 2025
General Payments
$1,146.52
27 reported records · 7 companies
Healthcare provider profile · identity verified
Thang Duc Tran, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN JOSE, CA · NPI 1275514069
Verified facts
What the public records show
CMS Open Payments records show Thang Duc Tran, MD received $1,146.52 in general payments during 2025 across 27 reported records.
ABBVIE INC. accounted for 40.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Licart.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vemlidy by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Licart as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Licart by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $459.30 | 40.1% | 12 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $247.44 | 21.6% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $124.55 | 10.9% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $121.08 | 10.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $116.74 | 10.2% | 6 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $40.94 | 3.6% | 2 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $36.47 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,146.52 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $247.44 | 4 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $246.19 | 7 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $124.55 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $121.08 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $40.94 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $40.94 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $40.94 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | MERZ NORTH AMERICA, INC. | $36.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Licart licart |
2025 | Licart | 2024 | 39 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Licart open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Licart · 2024 Exact normalized brand match · 1 Part D row |
39 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 698 | 195 |
| Losartan Potassium | Losartan Potassium | 587 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 503 | 150 |
| Omeprazole | Omeprazole | 345 | 95 |
| Fluticasone Propionate | Fluticasone Propionate | 316 | 107 |
| Metformin Hcl | Metformin Hcl | 303 | 88 |
| Jardiance | Empagliflozin | 296 | 54 |
| Simvastatin | Simvastatin | 253 | 67 |
| Gabapentin | Gabapentin | 248 | 79 |
| Montelukast Sodium | Montelukast Sodium | 244 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 194 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 55 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 181 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 110 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 30 |
| Farxiga | Dapagliflozin Propanediol | 104 | 30 |
| Lisinopril | Lisinopril | 102 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 28 |
| Alendronate Sodium | Alendronate Sodium | 92 | 30 |
| Mirtazapine | Mirtazapine | 91 | 21 |
| Vascepa | Icosapent Ethyl | 80 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 37 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 73 | 25 |
| Meloxicam | Meloxicam | 71 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 18 |
| Finasteride | Finasteride | 62 | 16 |
| Januvia | Sitagliptin Phosphate | 62 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 21 |
| Naproxen | Naproxen | 53 | 19 |
| Prednisone | Prednisone | 53 | 31 |
| Icosapent Ethyl | Icosapent Ethyl | 48 | 21 |
| Cromolyn Sodium | Cromolyn Sodium | 46 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 45 | 13 |
| Allopurinol | Allopurinol | 43 | 14 |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 11 |
| Fosinopril Sodium | Fosinopril Sodium | 40 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Licart | Diclofenac Epolamine | 39 | 16 |
| Famotidine | Famotidine | 37 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 14 |
| Azithromycin | Azithromycin | 36 | 29 |
| Hydrocortisone | Hydrocortisone | 36 | 18 |
| Eliquis | Apixaban | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Furosemide | Furosemide | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Loperamide | Loperamide Hcl | 29 | 26 |
| Tradjenta | Linagliptin | 29 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Amoxicillin | Amoxicillin | 23 | 21 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 18 |
| Glipizide | Glipizide | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 15 |
| Promethazine-Dm | Promethazine/Dextromethorphan | 19 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Benzonatate | Benzonatate | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Twinrix | Hepatitis A And B Vaccine/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,146.52 · 27 records | ABBVIE INC. | BOTOX, DAXXIFY, Flector, Leqembi, Licart, PURIFIED CORTROPHIN GEL, Tirosint, Xeomin | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Licart play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error